Edition:
India

DiaMedica Therapeutics Inc (DMAC.OQ)

DMAC.OQ on NASDAQ Stock Exchange Capital Market

2.89USD
13 Sep 2019
Change (% chg)

$-0.06 (-2.03%)
Prev Close
$2.95
Open
$2.95
Day's High
$2.95
Day's Low
$2.88
Volume
7,935
Avg. Vol
20,200
52-wk High
$5.90
52-wk Low
$2.21

Latest Key Developments (Source: Significant Developments)

Diamedica Therapeutics Announces Second Quarter Loss Per Share $0.21
Wednesday, 14 Aug 2019 

Aug 13 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.DIAMEDICA THERAPEUTICS INC - PHASE II CKD PROTOCOL SUBMITTED, TRIAL INITIATION EXPECTED H2 2019 WITH INTERIM ANALYSIS Q1 2020.DIAMEDICA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.21.  Full Article

Diamedica Says Phase 1B Trial Of Dm199 Demonstrated Dose Range For Chronic Kidney Disease Patients
Thursday, 20 Jun 2019 

June 19 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA THERAPEUTICS ANNOUNCES INTERIM RESULTS FROM PHASE 1B TRIAL OF DM199 IN CHRONIC KIDNEY DISEASE PARTICIPANTS.DIAMEDICA THERAPEUTICS INC - PHASE II TRIAL INITIATION EXPECTED 2H19 WITH INTERIM ANALYSIS Q4 2019 - Q1 2020.DIAMEDICA THERAPEUTICS INC - DM199 (RECOMBINANT KLK1) WAS OBSERVED TO BE SAFE AND WELL TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS.DIAMEDICA THERAPEUTICS - STUDY ALSO DEMONSTRATED DOSE RANGE WHICH COMPANY BELIEVES WILL RESTORE NORMAL KLK1 LEVELS IN CKD PATIENTS.  Full Article

DiaMedica Therapeutics Announces 2018 Financial Results
Wednesday, 20 Mar 2019 

March 19 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA THERAPEUTICS ANNOUNCES 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.DIAMEDICA THERAPEUTICS INC - TOTAL CASH RESOURCES WERE $16.8 MILLION AS OF DECEMBER 31, 2018, COMPARED TO $1.4 MILLION AS OF DECEMBER 31, 2017.  Full Article

DiaMedica Announces FDA Clearance Of IND Application To Study DM199 In Patients With Chronic Kidney Disease
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA ANNOUNCES FDA CLEARANCE OF IND APPLICATION TO STUDY DM199 IN PATIENTS WITH CHRONIC KIDNEY DISEASE.DIAMEDICA THERAPEUTICS INC - ANTICIPATE COMPLETING PHASE IB STUDY BY MID-2019 AND PHASE II STUDY IN Q4 2019 OR Q1 2020.  Full Article

Diamedica Announces Pricing Of Initial Public Offering And Nasdaq Listing
Friday, 7 Dec 2018 

Dec 7 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING.SAYS INITIAL PUBLIC OFFERING PRICED AT $4.00PER SHARE.COMMON SHARES ARE EXPECTED TO BEGIN TRADING DECEMBER 7, 2018 ON NASDAQ CAPITAL MARKET UNDER SYMBOL "DMAC.".  Full Article

Diamedica Therapeutics Applied To List Common Shares On Nasdaq, Announces Share Consolidation
Tuesday, 13 Nov 2018 

Nov 12 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA THERAPEUTICS HAS APPLIED TO LIST ITS COMMON SHARES ON NASDAQ, ANNOUNCES SHARE CONSOLIDATION.DIAMEDICA THERAPEUTICS - CONSOLIDATION ON BASIS OF 1 NEW COMMON SHARE FOR EVERY 20 CURRENTLY OUTSTANDING COMMON SHARES.  Full Article

DIAMEDICA THERAPEUTICS GETS ETHICS PANEL NOD TO BEGIN STROKE THERAPY TRIAL
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA THERAPEUTICS ANNOUNCES ETHICS COMMITTEE CLEARANCE AT FIRST SITE TO INITIATE REMEDY PHASE 2 TRIAL FOR ACUTE ISCHEMIC STROKE.DIAMEDICA THERAPEUTICS INC - ‍RECEIVED ETHICS COMMITTEE APPROVAL TO INITIATE FIRST CLINICAL SITE FOR ITS PHASE 2 REMEDY CLINICAL TRIAL WITH DM199​.  Full Article

Diamedica Therapeutics announces positive results for DM199
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Diamedica Therapeutics Inc :Diamedica Therapeutics announces publication of positive clinical results for DM199 in the international journal of clinical trials.  Full Article

No consensus analysis data available.